Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis (MkII)

E

EyePoint Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Non-Infectious Uveitis

Treatments

Drug: FAI Insert administered using the Mk I inserter
Drug: FAI Insert administered using the Mk II inserter

Study type

Interventional

Funder types

Industry

Identifiers

NCT02748512
PSV-FAI-006

Details and patient eligibility

About

This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.

Full description

This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the MK II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.

Enrollment

26 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or non-pregnant female at least 18 years of age at time of consent
  • At least one eye has a history of non-infectious uveitis affecting the posterior segment
  • Subject has ability to understand and sign the Informed Consent Form
  • Subject is willing and able to comply with study requirements

Exclusion criteria

  • Allergy to fluocinolone acetonide or any component of the FAI insert
  • Ocular malignancy in either eye, including choroidal melanoma
  • Uveitis with infectious etiology
  • Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
  • Current mycobacterial infections of the eye or fungal diseases of ocular structures
  • Subjects who yield, during screening, a confirmed positive test for human immune deficiency virus (HIV) or syphilis
  • Systemic infection within 30 days prior to study Day 1
  • Peripheral retinal detachment in area of insertion
  • Elevated intraocular pressure (IOP) > 21 mmHg, or chronic hypotony < 6 mmHg
  • Concurrent therapy at screening with IOP-lowering pharmacologic agent in the study eye
  • Current diagnosis of any form of glaucoma or ocular hypertension in study eye at Screening, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (10-21 mmHg)
  • Known history of clinically significant IOP elevation in response to steroid treatment in either eye, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (10-21 mmHg)
  • Ocular surgery or capsulotomy performed on the study eye within 30 days prior to study Day 1
  • Intravitreal treatment of study eye: with FAI insert within 36 months prior to study Day 1;with Retisert within 30 months prior to study Day 1; with Ozurdex within 90 days prior to study Day 1; or with Triesence or Trivaris within 30 days prior to study Day 1
  • Peri-ocular or subtenon steroid treatment of study eye within 30 days prior to study Day 1
  • Treatment with an investigational drug or device within 30 days prior to study Day 1, except the FAI insert within this protocol
  • Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the Month 12 Visit
  • Any condition which, in the judgment of the Investigator, could make the subject inappropriate for entry into this study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

26 participants in 2 patient groups

FAI Insert administered using the Mk II inserter
Experimental group
Description:
The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
Treatment:
Drug: FAI Insert administered using the Mk II inserter
FAI Insert administered using the Mk I inserter
Active Comparator group
Description:
The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
Treatment:
Drug: FAI Insert administered using the Mk I inserter

Trial documents
2

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems